Ascendis Pharma Says FDA Extending Review Period for NDA
By Ben Glickman
Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information.
The Danish biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration had informed the company that its new target date was Aug. 14, compared with its previous date of May 14.
Ascendis's new drug application for TransCon, or palopegteriparatide, in treatment of adults with hypoparathyroidism was accepted by the FDA in December.
The FDA can extend review periods for NDAs if there are major amendments to the applications.
Ascendis Chief Executive Jan Mikkelsen said the company had responded to all requests received from FDA at this point and is committed to bringing the treatment to patients.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 14, 2024 15:11 ET (19:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks